Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
40.47
+0.32 (0.80%)
At close: Nov 18, 2025, 4:00 PM EST
40.70
+0.23 (0.57%)
After-hours: Nov 18, 2025, 7:54 PM EST
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Arrowhead Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $47.44, which forecasts a 17.22% increase in the stock price over the next year. The lowest target is $17 and the highest is $80.
Price Target: $47.44 (+17.22%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 3 | 3 | 2 | 2 |
| Hold | 3 | 3 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 8 | 9 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $29 → $45 | Hold | Maintains | $29 → $45 | +11.19% | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +97.68% | Oct 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +97.68% | Sep 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +48.26% | Aug 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $40 → $38 | Buy | Maintains | $40 → $38 | -6.10% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
759.46M
from 3.55M
Increased by 21,287.21%
Revenue Next Year
421.66M
from 759.46M
Decreased by -44.48%
EPS This Year
0.08
from -5.00
EPS Next Year
-2.75
from 0.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 969.2M | 679.1M | ||||
| Avg | 759.5M | 421.7M | ||||
| Low | 561.5M | 99.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27,192.3% | -10.6% | ||||
| Avg | 21,287.2% | -44.5% | ||||
| Low | 15,713.6% | -86.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.97 | -0.87 | ||||
| Avg | 0.08 | -2.75 | ||||
| Low | -1.04 | -4.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.